×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: AMPK Activator Therapies
therapeutic
1,559 words
KG: ent-prot-60b92a1d
2026-03-26
kind:therapeutic
section:therapeutics
state:published
Contents
AMPK Activator Therapies
💊
Therapeutic Info
Name
AMPK Activator Therapies
Summary
AMPK pathway activation for metabolic stress response and neuroprotection in Parkinson's disease.
Knowledge Graph
Related Hypotheses (20)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
Circadian-Synchronized Proteostasis Enhancement
Score: 0.58
TFEB-Independent Autophagy Bypass
Score: 0.51
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62
APOE-Dependent Autophagy Restoration
Score: 0.61
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.57
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Circadian Clock-Autophagy Synchronization
Score: 0.55
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Temporal Decoupling via Circadian Clock Reset
Score: 0.52
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.49
APOE Isoform Expression Across Glial Subtypes
Score: 0.48
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.46
Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45
APOE Isoform Conversion Therapy
Score: 0.44
Microglia-Derived Extracellular Vesicle Engineering for Targ
Score: 0.37
Show 15 more
Related Analyses (7)
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Show 2 more
Related Experiments (21)
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · proposed · Score: 0.90
Germfree mouse colonocyte energy metabolism analysis
validation · proposed · Score: 0.90
AMPK knockdown validation experiment
exploratory · proposed · Score: 0.88
iPSC-NPC transplantation in ICH animal model
validation · proposed · Score: 0.85
Proposed experiment from debate on Astrocytes adopt A1 (neur
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Selective Vulnerability of Dopaminergic Neurons — Mechanism
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
GLP-1 Agonist Responder Prediction Study — Precision Medicin
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Metabolic Syndrome-Parkinson's Disease Axis Clinical Trial
clinical · proposed · Score: 0.40
Peroxisome Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Selective Neuronal Vulnerability to Aging — Mapping Why Spec
validation · proposed · Score: 0.40
Sirtuin Pathway Dysfunction Validation in Parkinson's Diseas
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
Show 16 more